<DOC>
	<DOC>NCT00357539</DOC>
	<brief_summary>To compare the ocular tolerance, safety and ocular pharmacokinetics of 3 concentrations (0.5% - 1.0% - 1.5%) and the vehicle of T1225.</brief_summary>
	<brief_title>Safety and Ocular Pharmacokinetics After 1 Drop of T1225 0.5, 1 and 1.5% in 48 Healthy Volunteers</brief_title>
	<detailed_description>The present phase I clinical trial was performed in order to investigate the ocular tolerance, safety and the ocular pharmacokinetics of a single administration of T1225 eye drops (0.5%, 1.0%, or 1.5%) in healthy volunteers.</detailed_description>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Eye Infections</mesh_term>
	<mesh_term>Eye Infections, Bacterial</mesh_term>
	<criteria>Male or female aged from 18 to 45 years old; Written informed consent; Healthy volunteers (without any ocular symptom); Normal ocular examination in both eyes (corrected visual acuity (VA) &gt;= 6/10 slit lamp examination without clinical relevant abnormalities tear breakup time (BUT) &gt;= 10 seconds lachrymal secretion in the Schirmer test &gt;= 10 mm in 5 minutes lissamine green test total score &lt; 4). Ocular trauma, infection or inflammation within the last 3 months; Conjunctival hyperaemia score &gt;= 2, watering score &gt;= 2, folliculopapillary conjunctivitis score &gt;= 2, number of fluoresceinstained punctuations &gt;= 10; Blepharitis, conjunctivitis, uveitis; Ocular laser treatment within the last 3 months; Ocular surgery, including LASIK and PRK, within the last 12 months; Topical ocular treatment during the last month; Ocular antibiotics within the last 7 days; Medication during the study (except paracetamol and contraceptives).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2006</verification_date>
</DOC>